JP2009519935A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519935A5
JP2009519935A5 JP2008545740A JP2008545740A JP2009519935A5 JP 2009519935 A5 JP2009519935 A5 JP 2009519935A5 JP 2008545740 A JP2008545740 A JP 2008545740A JP 2008545740 A JP2008545740 A JP 2008545740A JP 2009519935 A5 JP2009519935 A5 JP 2009519935A5
Authority
JP
Japan
Prior art keywords
volume
mass
aqueous pharmaceutical
pharmaceutical suspension
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519935A (ja
JP5308824B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/047393 external-priority patent/WO2007070517A2/en
Publication of JP2009519935A publication Critical patent/JP2009519935A/ja
Publication of JP2009519935A5 publication Critical patent/JP2009519935A5/ja
Application granted granted Critical
Publication of JP5308824B2 publication Critical patent/JP5308824B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545740A 2005-12-14 2006-12-12 フェキソフェナジン懸濁液製剤 Expired - Fee Related JP5308824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14
US60/750,303 2005-12-14
PCT/US2006/047393 WO2007070517A2 (en) 2005-12-14 2006-12-12 Fexofenadine suspension formulation

Publications (3)

Publication Number Publication Date
JP2009519935A JP2009519935A (ja) 2009-05-21
JP2009519935A5 true JP2009519935A5 (cg-RX-API-DMAC7.html) 2010-01-21
JP5308824B2 JP5308824B2 (ja) 2013-10-09

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545740A Expired - Fee Related JP5308824B2 (ja) 2005-12-14 2006-12-12 フェキソフェナジン懸濁液製剤

Country Status (38)

Country Link
US (1) US8933097B2 (cg-RX-API-DMAC7.html)
EP (1) EP1965768B1 (cg-RX-API-DMAC7.html)
JP (1) JP5308824B2 (cg-RX-API-DMAC7.html)
KR (1) KR101452792B1 (cg-RX-API-DMAC7.html)
CN (1) CN101316580B (cg-RX-API-DMAC7.html)
AR (1) AR058323A1 (cg-RX-API-DMAC7.html)
AT (1) ATE431137T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006326551B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0619895B1 (cg-RX-API-DMAC7.html)
CA (1) CA2633086C (cg-RX-API-DMAC7.html)
CR (1) CR9993A (cg-RX-API-DMAC7.html)
CY (1) CY1109320T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006006870D1 (cg-RX-API-DMAC7.html)
DK (1) DK1965768T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2006000274A (cg-RX-API-DMAC7.html)
EC (1) ECSP088532A (cg-RX-API-DMAC7.html)
EG (1) EG25866A (cg-RX-API-DMAC7.html)
ES (1) ES2327168T3 (cg-RX-API-DMAC7.html)
HN (1) HN2008000875A (cg-RX-API-DMAC7.html)
HR (1) HRP20090411T1 (cg-RX-API-DMAC7.html)
IL (1) IL192067A (cg-RX-API-DMAC7.html)
JO (1) JO2549B1 (cg-RX-API-DMAC7.html)
MA (1) MA30152B1 (cg-RX-API-DMAC7.html)
MY (1) MY146988A (cg-RX-API-DMAC7.html)
NO (1) NO339877B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ568943A (cg-RX-API-DMAC7.html)
PE (1) PE20071003A1 (cg-RX-API-DMAC7.html)
PL (1) PL1965768T3 (cg-RX-API-DMAC7.html)
PT (1) PT1965768E (cg-RX-API-DMAC7.html)
RS (1) RS51135B (cg-RX-API-DMAC7.html)
RU (1) RU2405538C2 (cg-RX-API-DMAC7.html)
SI (1) SI1965768T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN08186A1 (cg-RX-API-DMAC7.html)
TW (1) TWI377061B (cg-RX-API-DMAC7.html)
UA (1) UA89584C2 (cg-RX-API-DMAC7.html)
UY (1) UY30021A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007070517A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200803985B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
JP2016523928A (ja) * 2013-07-03 2016-08-12 アール.ピー.シェーラー テクノロジーズ、エルエルシー フェキソフェナジンを有するカプセル製剤
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
CA3027434C (en) * 2016-06-16 2025-02-04 Cutispharma, Inc. COMPOSITION AND METHOD FOR SUSPENDING A PROTON PUMP INHIBITOR
KR102642434B1 (ko) 2017-06-02 2024-02-29 테이카 세이야쿠 가부시키가이샤 난수용성 성분 가용화 미셀 및 그것을 함유하는 액제
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
WO2022038474A1 (en) * 2020-08-18 2022-02-24 Innate S.R.L. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
EP4456880A1 (en) * 2021-12-29 2024-11-06 Opella Healthcare Group SAS Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
WO2024153354A1 (en) 2023-01-20 2024-07-25 Opella Healthcare Group Sas Paraben-free fexofenadine formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
EP0766668B1 (en) 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
ATE444731T1 (de) 2003-01-30 2009-10-15 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
PT2486942T (pt) * 2004-11-24 2019-01-18 Meda Pharmaceuticals Inc Composições que compreendem azelastina e seus métodos de utilização
MX2008001246A (es) 2005-07-27 2008-03-18 Sandoz Ag Un proceso para la preparacion de compuestos de fenil eter substituidos y rosiglitazona.
US20080274196A1 (en) * 2005-08-05 2008-11-06 Lipin Limited Oral Pharmaceutical Suspension Compositions Of Fexofenadine

Similar Documents

Publication Publication Date Title
JP2009519935A5 (cg-RX-API-DMAC7.html)
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
CA2668733C (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
CA2633086A1 (en) Fexofenadine suspension formulation
KR101646079B1 (ko) 트립탄 화합물을 포함하는 제제
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
NZ208127A (en) Pharmaceutical compositions containing ranitidine
PT85468B (pt) Processo de preparacao de composicoes farmaceuticas estaveis a base de cimetidina
KR20100087002A (ko) 발사르탄을 포함하는 액체 조성물
US20090048344A1 (en) Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
WO2016159897A1 (en) Potassium citrate suspension
CN102078285A (zh) 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
JPS63215622A (ja) 経口投与用医薬組成物
US20150034087A1 (en) Low Dose Pharmaceutical Composition Comprising Zanamivir
PE20030970A1 (es) Formulacion de aerosol para inhalacion que contiene una sal de tiotropio
JP2009516001A (ja) リポキシゲナーゼ阻害剤とシクロデキストリンとを含む組成物
CN102078612A (zh) 含有糠酸莫米松和h1受体拮抗剂的鼻用原位凝胶
JP4956981B2 (ja) オキシメタゾリン含有水性組成物
CN102933198B (zh) 包含曲普坦化合物的制剂
CN102362855A (zh) 一种伊曲康唑异构体口服溶液
WO2022007743A1 (zh) 粘膜给药剂型和其应用
JP3364453B2 (ja) センノシド含有水性液剤
JP5311825B2 (ja) 2−イミダゾリン構造を有するα−交感神経興奮薬の新規な使用
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
WO2004000320A1 (ja) 水性点眼用製剤